Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Apexigen
Apexigen is a biopharmaceutical company developing products to treat life-threatening and difficult to treat diseases.
Sector
Subsector
Location
total rounds
total raised
AltruBio
AltruBio is a biopharmaceutical company developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Immune Pharmaceuticals
Immune Pharmaceuticals develops personalized antibody therapeutics for inflammatory diseases and cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Celsion
Celsion is a biopharmaceutical company developing innovative cancer treatments.
Sector
Subsector
Location
total rounds
total raised
Financials
Funding Rounds8
Number of Funding Rounds
Money Raised
Their latest funding was raised on 29.02.2024. Their latest round Post-IPO Equity
Co-Investors
Acquisitions4
Kolltan Pharmaceuticals acquired by Celldex Therapeutics
acquirer
date
type
price
Kolltan Pharmaceuticals
Kolltan Pharmaceuticals develops new-generation monoclonal antibody oncology therapeutics.
Sector
Subsector
Keywords
Location
total rounds
total raised
Curagen Corporation acquired by Celldex Therapeutics
acquirer
date
type
Curagen Corporation
CuraGen Corporation is a biopharmaceutical development company focused on developing innovative cancer therapeutics.
Sector
Subsector
Keywords
Location
Lorantis acquired by Celldex Therapeutics
acquirer
date
type
Lorantis
Lorantis develops products for the selective treatment of immunological and inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders3
Tibor Keler
Dr. Keler is a Founder of Celldex and serves as the Company’s Executive Vice President and Chief Scientific Officer. Prior to this appointment in 2014, he was Senior Vice President of Research and Discovery at Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). Previously, Dr. Keler was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. While at Medarex, he was responsible for the preclinical development of a number of Medarex clinical product candidates. In addition, Dr. Keler was responsible for the development of Celldex's core technology and related products. Dr. Keler received his Ph.D. in Microbiology from the University of Pennsylvania.
current job
organization founded
Tibor Keler
Anthony S. Marucci
Mr. Marucci is a Founder of Celldex and serves as the Company’s President and Chief Executive Officer and as a member of the Board of Directors. Prior to his appointment as President and CEO in 2008, Mr. Marucci served as Vice President, Chief Financial Officer, Treasurer and Secretary of Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). In addition to these acquisitions, Mr. Marucci is also responsible for the AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. merger completed during the first quarter of 2008 and the acquisition of CuraGen Corporation completed in the third quarter of 2009. He was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions since December 1998. He is a member of the Board of Trustees of BioNJ and also served as its Treasurer through 2010. Mr. Marucci received his B.S. in Accounting from Kean University and his M.B.A. from Columbia University.
current job
organization founded
Anthony S. Marucci
Harry H. Penner
Mr. Penner is Founder, Chairman and Chief Executive Officer of Nascent BioScience, LLC, a firm engaged in the creation and development of new biotechnology companies founded in September 2001. Mr. Penner is a Founder of New Haven Pharmaceuticals (of which he is Chairman and Chief Executive Officer), Prevention Pharmaceuticals, Affinimark Technologies, Rib-X Pharmaceuticals, RxGen, MAK Scientific, and Celldex Therapeutics. He was President, Chief Executive Officer, and Vice Chairman of Neurogen Corporation from 1993 to 2001. From 1985 to 1993 he was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America, and from 1985 to 1988 as the company's Executive Vice President and General Counsel in Denmark. He has served as BioScience Advisor to the Governor and the State of Connecticut, as Co-Chair of Connecticut United for Research Excellence, and as Chair of the Connecticut Board of Governors of Higher Education. He currently serves on the Boards Rib-X, New Haven Pharmaceuticals, Prevention Pharmaceuticals, and Affinimark. Mr. Penner holds a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New York University.
current job
organization founded
Harry H. Penner
Employee Profiles72
Lawrence Thomas
Vice president, preclinical r and d and bioanalytics
Carrie Domozick
Associate director of quality control
Eric Forsberg
Associate director, bioanalytics at celldex therapeutics
Richard Khazzaka
Executive director, manufacturing operations and supply
Diane Young
Sr Vice President and Chief Medical Officer
Shannon Renn-Bingham
Senior manager, analytical development
Anja Pilja
Human resources generalist and business partner
Activity
Recent News6
The graph reveals the ratio (%) of positive news articles in a chosen time range